| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 779 |
| 1 | NIVOLUMAB | 508 |
| 2 | IPILIMUMAB | 288 |
| 3 | CARBOPLATIN | 196 |
| 4 | PACLITAXEL | 137 |
| 5 | PACLITAXEL (AIBUMIN-BOUND) | 130 |
| 6 | DURVALUMAB | 113 |
| 7 | DOXORUBICIN | 79 |
| 8 | PEMETREXED DISODIUM | 77 |
| 9 | CISPLATIN | 70 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ACETAMINOPHEN TABLETS 500 MG | 1 | 0.1429 |
| 1 | ADENINE | 1 | 0.0204 |
| 2 | PENPULIMAB | 2 | 0.0204 |
| 3 | NIVOLUMAB AND RELATLIMAB-RMBW | 6 | 0.0117 |
| 4 | TREMELIMUMAB | 45 | 0.0102 |
| 5 | NIVOLUMAB AND HYALURONIDASE-NVHY | 1 | 0.0074 |
| 6 | PEMBROLIZUMAB | 779 | 0.0072 |
| 7 | IPILIMUMAB | 288 | 0.0066 |
| 8 | HETASTARCH | 1 | 0.0059 |
| 9 | DOSTARLIMAB | 14 | 0.0056 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1354 | 0.0137 |
| 1 | Lymphocyte Activation Gene-3 Blocker [EPC] | 6 | 0.0117 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 333 | 0.0069 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 121 | 0.0056 |
| 4 | Interleukin-36 Receptor Antagonist [EPC] | 1 | 0.0025 |
| 5 | Platinum-based Drug [EPC] | 307 | 0.0011 |
| 6 | Microtubule Inhibitor [EPC] | 155 | 0.0009 |
| 7 | Endoglycosidase [EPC] | 1 | 0.0005 |
| 8 | Guanylate Cyclase-C Agonist [EPC] | 1 | 0.0005 |
| 9 | Orexin Receptor Antagonist [EPC] | 8 | 0.0004 |